Sapacitabine: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 60 elderly patients with AML showed that 1-year survival rates were 35%, 10% and 30% for the 200, 300 and 400 mg sapacitabine arms, respectiv...